<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        
        
        
        <link rel="shortcut icon" href="../../img/favicon.ico">
        <title>Breast cancer - MediWiki</title>
        <link href="../../css/bootstrap.min.css" rel="stylesheet">
        <link href="../../css/font-awesome.min.css" rel="stylesheet">
        <link href="../../css/base.css" rel="stylesheet">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/color-brewer.min.css">
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
        <script>hljs.highlightAll();</script> 
    </head>

    <body>
        <div class="navbar fixed-top navbar-expand-lg navbar-dark bg-primary">
            <div class="container">
                <a class="navbar-brand" href="../..">MediWiki</a>
                <!-- Expander button -->
                <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#navbar-collapse">
                    <span class="navbar-toggler-icon"></span>
                </button>

                <!-- Expanded navigation -->
                <div id="navbar-collapse" class="navbar-collapse collapse">
                        <!-- Main navigation -->
                        <ul class="nav navbar-nav">
                            <li class="navitem">
                                <a href="../../Basic%20Clinical%20Sciences.html" class="nav-link">Basic Clinical Sciences</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Internal%20Medicine.html" class="nav-link">Internal Medicine</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Surgery.html" class="nav-link">Surgery</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Psychiatry.html" class="nav-link">Psychiatry</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Critical%20Care.html" class="nav-link">Critical Care</a>
                            </li>
                        </ul>

                    <ul class="nav navbar-nav ml-auto">
                        <li class="nav-item">
                            <a href="#" class="nav-link" data-toggle="modal" data-target="#mkdocs_search_modal">
                                <i class="fa fa-search"></i> Search
                            </a>
                        </li>
                            <li class="nav-item">
                                <a rel="prev" href="Bladder%20cancer.html" class="nav-link">
                                    <i class="fa fa-arrow-left"></i> Previous
                                </a>
                            </li>
                            <li class="nav-item">
                                <a rel="next" href="Cancer%20Genetics.html" class="nav-link">
                                    Next <i class="fa fa-arrow-right"></i>
                                </a>
                            </li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="container">
            <div class="row">
                    <div class="col-md-3"><div class="navbar-light navbar-expand-md bs-sidebar hidden-print affix" role="complementary">
    <div class="navbar-header">
        <button type="button" class="navbar-toggler collapsed" data-toggle="collapse" data-target="#toc-collapse" title="Table of Contents">
            <span class="fa fa-angle-down"></span>
        </button>
    </div>

    
    <div id="toc-collapse" class="navbar-collapse collapse card bg-secondary">
        <ul class="nav flex-column">
            
            <li class="nav-item" data-level="1"><a href="#breast-cancer" class="nav-link">Breast cancer</a>
              <ul class="nav flex-column">
            <li class="nav-item" data-level="2"><a href="#background" class="nav-link">Background</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#false-positive-mammograms" class="nav-link">False positive mammograms</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#breast-cancer-primary-factors-in-prognostication" class="nav-link">Breast cancer primary factors in prognostication</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#her2neu-and-trastuzumab" class="nav-link">HER2/neu and trastuzumab</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#diagnosis" class="nav-link">Diagnosis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#management-of-breast-cancers" class="nav-link">Management of breast cancers</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#_1" class="nav-link"></a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#complications" class="nav-link">Complications</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#bone-metastases" class="nav-link">Bone metastases</a>
              <ul class="nav flex-column">
              </ul>
            </li>
              </ul>
            </li>
        </ul>
    </div>
</div></div>
                    <div class="col-md-9" role="main">

<h1 id="breast-cancer">Breast cancer</h1>
<h2 id="background">Background</h2>
<ul>
<li>In the united states, 1 in 8 women develop breast cancer<ul>
<li>most common cancer in women; 2nd most common cause of cancer mortality</li>
</ul>
</li>
<li>Risk factors which increase risk of breast cancer are those which increase estrogen exposure<ul>
<li>Increased age (increased exposure time) - median onset is 61 years old</li>
<li><strong>BRCA1/2 mutation</strong><ul>
<li>BRCA1: 50-70% breast, 40-50% ovarian</li>
<li>BRCA2: 45-70% breast, 15-20% ovarian<ul>
<li>increased male breast cancer risk</li>
</ul>
</li>
<li>increased pancreatic and prostate cancer risk in BRCA1/2</li>
<li>BRCA1/2 only explains 5-10% of breast cancers - MOST breast cancers are not genetically related</li>
</ul>
</li>
<li>Chest irradiation (e.g. previous non-hodgkins lymphoma in childhood)</li>
<li>Atypical lesions present (e.g. atypical hyperplasia, lobular carcinoma)</li>
<li>hereditary syndromes (e.g. FHx Breast cancer, ovarian, tubal)</li>
<li>Reproductive factors (early menarche, late menopause, first full-term pregnancy after 30y/o, nulliparity) → i.e. longer menstrual period with less pregnancy time</li>
<li>Lifestyle (<strong>obesity</strong>, BMI &gt; 30, lack of regular exercise, increased <strong>EtOH</strong>)<ul>
<li>most relevant to post-menopausal breast cancer risk - 20-30% increased risk with BMI &gt; 30 - due to main source of estrogen in postmenopauseal being by aromatase in adipose tissue<ul>
<li>estrodiol levels increase, SHBG (bound estrogen) levels gone down with increasing BMI</li>
</ul>
</li>
<li>NO increased risk in premenopausal breast cancer risk</li>
<li>breast cancer risk lowers with regular activity<ul>
<li>reduced weight gain, body fat → decreases estrodiol, estrone, free estradiol, increased SHBG</li>
<li>reduced insulin levels → protective (potentially)</li>
<li>increased activity (met-hours) results in reduced postmenopauseal breast cancer; however no strong association with moderate/strenuous activity (just few minutes of exercise/wk is enough)</li>
</ul>
</li>
<li>EtOH intake associated with increased breast cancer<ul>
<li>EtOH intake increases estrone and estradiol levels → breast cancer risk</li>
</ul>
</li>
</ul>
</li>
<li>Hormone replacement therapy (combined ESTROGEN and progesterone)</li>
<li>increased breast density</li>
</ul>
</li>
<li>Different countries have different breast cancer screening guidelines<ul>
<li>Australia's breast cancer screening guidelines as a baseline recommend everyone from age <strong>50-74</strong> to be screened regardless of risk<ul>
<li>mammograms DO reduce mortality for women aged 40-49 in US<ul>
<li>against:<ul>
<li>large RCTs (100000+) show 15-25% decrease in mortality but not statistically significant</li>
<li>breast cancer less risk for aged &lt; 50</li>
<li>older studies done before modern treatments - not applicable to present (but would therefore underestimate benefit?)</li>
<li>many more false positives in women 40-49</li>
</ul>
</li>
<li>for:<ul>
<li>large meta-analyses show significant 7-23% reduction in mortality → however needs a LOT of people to be screened for it to be effective</li>
<li>breast cancer is leading cause of death aged 40-49</li>
</ul>
</li>
</ul>
</li>
<li>MRI has not had head-on comparisons against mammography to reduce breast cancer</li>
<li>multiple randomised trials show 15-20% mortality with screening mammography use</li>
<li>recommended screening interval is 1-2 years</li>
</ul>
</li>
<li>these guidelines are augmented on a patent-by-patient scale depending on presence of risk factors in the family<ul>
<li>presence of risk factors means you may be indicated to be screened YEARLY from 40 years onwards</li>
</ul>
</li>
<li>Risk factors for increased BCa screening as per the Australian guidelines include<ul>
<li>Moderately increased risk<ul>
<li>1x 1st degree BCa &lt; 50Y</li>
<li>2x ist degree same side BCa</li>
<li>2x 2nd degree same side relatives, with 1x &lt; 50</li>
</ul>
</li>
<li>Potentially higher risk<ul>
<li>increased risk of ovarian cancer due to other factors</li>
<li>2x 1st degree or 2x 2nd degree same side relatives with breast or ovarian cancer WITH<ul>
<li>additional relatives with BCa/OCa</li>
<li>BCa &lt; 40 years</li>
<li>bilateral BCa</li>
<li>either relative having both BCa and OCa</li>
<li>Ashkenazi Jewish background</li>
<li>Male BCa</li>
</ul>
</li>
<li>1st degree or 2nd degree same side BCa &lt; 45 with a 1st/2nd degree same side sarcoma</li>
<li>family member with a high risk genetic mutation (E.g. BRCA1/2)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="false-positive-mammograms">False positive mammograms</h2>
<ul>
<li>~ 5% mammograms are false positives → 20-50% cumulative risk over 10 years<ul>
<li>more common in women &lt; 50y</li>
<li>main issue is population and healthcare economics POV</li>
</ul>
</li>
<li>overdiagnosis results in overtreatment<ul>
<li>5-50% of treated breast cancer detected on screen may be overdiagnosis</li>
<li>seen in DCIS and small invasive cancers</li>
<li>increasingly sensitive radiologic techniques may result in identification of problems which do not have clinical relevance!</li>
</ul>
</li>
<li>DCIS<ul>
<li>20% of memmographically detected lesions</li>
<li>however natural history of DCIS is unclear <ul>
<li>14-40% estimated to recur if untreated - but largest study (Eusebi 1994) is with 80 people; there is no evidence to see what happens to untreated DCIS</li>
<li>cannot reliably identify those that recur → everyone gets treated with mastectomy/lumpectomy +/- RCT +/- tamoxifen</li>
<li>is DCIS even really cancer? e.g. cervical carcinoma in situ now called CIN III and treatment has changed - cells look similar to invasive disease but basement membrane not involved</li>
</ul>
</li>
</ul>
</li>
<li>LCIS (lobular)<ul>
<li>increased risk of bilateral breast cancer without predictable location → does not need surgical excision</li>
<li>manage with observation or tamoxifen (NOT bilateral mastectomy)</li>
<li>increases likelihood of developing future breast cancer with incidence of ~ 1% per year </li>
</ul>
</li>
<li>Breast density<ul>
<li>hard to see breast cancer in a dense breast - as breast cancers appear as white/dense</li>
<li>associated with increased risk of breast cancer<ul>
<li>NOT actually related to being unable to see the breast cancer</li>
<li>dense tissue tends to have a higher risk of breast cancer even when controlled for this</li>
</ul>
</li>
<li>ultrasound best for targeted areas but NOT whole breast</li>
<li>MRI has high rate of false positives for these women<ul>
<li>more sensitive especially in younger women, but does NOT replace mammograms</li>
<li>many more false positives than mammography</li>
<li>not practical as a screening tool - takes 45 minutes to do, requires more human resources to comment on the images</li>
<li>recommended for<ul>
<li>BRCA1/2, Li-Fraumeni (p53), Cowdens (pTEN)</li>
<li>lifetime risk of &gt;20-25%</li>
<li>radiation to chest (e.g. for Hodgkin's) between ages 10-30</li>
</ul>
</li>
</ul>
</li>
<li>consider breast tomosynthesis (3D mammogram) - XR machine moves to take multiple images of the breast<ul>
<li>3D tomosynthesis vs. 2D → no RCTs to compare - but reduced recall rate and increased cancer detection rate</li>
</ul>
</li>
</ul>
</li>
</ul>
<p><img alt="" src="../../figures/Pasted%20image%2020231025114313.png" /></p>
<h2 id="breast-cancer-primary-factors-in-prognostication">Breast cancer primary factors in prognostication</h2>
<h3 id="prognostic-factors">Prognostic factors</h3>
<table>
<thead>
<tr>
<th>Good prognostic factor</th>
<th>Desc</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER2 negativity</td>
<td>prognostically beneficial if NOT metastatic</td>
</tr>
<tr>
<td>ER/PR positivity (Hormone receptor positive)</td>
<td>Targeted treatments to hormone positive cancers. This includes Selective Estrogen Receptor Modulators (SERMs) such as tamoxifen, and aromatase inhibitor (e.g. letrozole)</td>
</tr>
<tr>
<td>Smaller tumour size</td>
<td>.</td>
</tr>
<tr>
<td>Lower grade tumour</td>
<td></td>
</tr>
<tr>
<td>Negative lymph nodes</td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="classifications-of-breast-cancer">Classifications of breast cancer</h3>
<ol>
<li>ER positive and HER2 negative (Luminal A) - hormonal therapy +/- chemo</li>
<li>ER positive and HER2 positive (Luminal B) - hormonal therapy +/- trastuzumab + chemo</li>
<li>ER negative and HER2 positive (HER2 enriched) - chemo + trastuzumab</li>
<li>Triple negative (Basaloid) - no targeted therapy (just chemo)</li>
</ol>
<h3 id="cancer-genetics">Cancer genetics</h3>
<ul>
<li>Management of breast cancer changes based on cancer genetics</li>
<li>this also offers prognostic information (alongside staging)</li>
<li>Things we consider are<ul>
<li>HER2 positivity → HER2 (human epidermal growth receptor 2) positivity is BAD if it is a tumour with a curative intent. If it is advanced/noncurative, it has better prognostication as there are HER2 monoclonal antibodies available to us</li>
<li>Hormone receptor positivity → ER/PR positive is GOOD as we have targeted hormonal therapies available</li>
</ul>
</li>
<li>BRCA1/2 mutation risk greater if<ul>
<li>age &lt; 50 at diagnosis</li>
<li>bilateral breast cancer</li>
<li>male breast cancer</li>
<li>triple negative breast cancer &lt; 60</li>
<li><em>test person with cancer first</em></li>
</ul>
</li>
<li>multigene/expanded panel testing<ul>
<li>CDH1, ATM, p53, PALB2, CHK2, pTEN, NBN, NF1, STK11, etc. → lifetime risk nowhere near BRCA1/2</li>
<li>clinical recommendations unclear</li>
</ul>
</li>
<li>OncotypeDX - 21 genes to estimate recurrence risk - good at identifying low, intermediate and high risk DISTANT recurrence (i.e. not within breast)<ul>
<li>specifically for ER positive tumours - node negative and 1-3 positive lymph nodes<ul>
<li>node negative - low score indicate &lt; 1-5% recurrence → no need for chemotherapy</li>
<li>TAILORx study - indicates for node negative ER+, low score, combined chemo therapy does not improve survival over hormonal therapy alone</li>
</ul>
</li>
<li>Proliferation - Ki67, STK15, Survivin, CCNB1 (cyclin B1), MYBL2</li>
<li>invasion - MMP11, CTSL2</li>
<li>HER2 - HER2, GRB7</li>
<li>GSTM1</li>
<li>CD68</li>
<li>BAG1</li>
<li>Estrogen - ER, PGR, BCL2, CUBE2</li>
<li>Reference - ACTB, BAPDH, RPLPO, GUS, TFRC</li>
</ul>
</li>
</ul>
<h2 id="her2neu-and-trastuzumab">HER2/neu and trastuzumab</h2>
<ul>
<li>HER2/neu (c-erbB2) protooncogene - 185kd transmembrane factor receptor<ul>
<li>20-25% breast cancer overexpress HER2<ul>
<li>IHC +2 or FISH ratio &gt; 2.0</li>
</ul>
</li>
</ul>
</li>
<li>trastuzumab - monoclonal ab against HER2<ul>
<li>can cause congestive HF → never administered with anthracycline</li>
</ul>
</li>
<li>HER2+ have WORSE prognosis if not treated with trastuzumab<ul>
<li>50% reduction in recurrence (Perez 2005)</li>
</ul>
</li>
<li>trastuzumab binds to extracellular HER2</li>
<li>pertuzumab prevents coreceptor binding of HER2 and HER1/2/3/4</li>
<li>Lapatinib binds TKI (intracellular HER2)</li>
</ul>
<p>### Adjuvant hormonal therapy
- 1st targeted therapy
    - reduced breast cancer mortality by 33%, contralateral breast cancver by 50%
    - 5 year tx for stage I, 10y tx for node positive cancers
- tamixofen - used in pre and postmenopausal
    - raloxifen can be used as primary prevention but not in adjuvant setting
- AIs - preferred for postmenopausal women
- ovarian suppression for high risk women</p>
<h3 id="staging">Staging</h3>
<h2 id="diagnosis">Diagnosis</h2>
<ul>
<li>Diagnosis of breast cancer in Australia is done with the 'triple test'<ol>
<li>Clinical History</li>
<li>Imaging - mammography or ultrasound</li>
<li>FNA biopsy</li>
</ol>
</li>
</ul>
<h2 id="management-of-breast-cancers">Management of breast cancers</h2>
<h3 id="stage-0-ductal-carcinoma-in-situ">Stage 0 - Ductal Carcinoma in Situ</h3>
<ul>
<li>Background<ul>
<li>Very early stage cancer</li>
</ul>
</li>
<li>Clinical features<ul>
<li>Rarely presents with palpable mass or Paget's disease of the breast</li>
</ul>
</li>
<li>Investigations<ul>
<li>No need for further imaging</li>
</ul>
</li>
<li>Therapeutic aim - curative<ul>
<li>Eradicate area and reduce local recurrence rates</li>
</ul>
</li>
<li>Management options<ol>
<li>Surgical local resection<ul>
<li>Lumpectomy (Wide excision) first line</li>
<li>Mastectomy considered if primary cannot be removed by wide excision</li>
</ul>
</li>
<li>Adjuvant radiotherapy - improves disease free survival but not BCa specific mortality</li>
<li>Adjuvant hormonal therapy (if ER positive)<ul>
<li>Pre-menopausal: Tamoxifen</li>
<li>Post-menopausal: Tamoxifen/raloxifene or aromatase inhibitor (e.g. anastrazole)</li>
</ul>
</li>
</ol>
</li>
<li>Follow-up<ul>
<li>6-12 monthly for 5 years</li>
<li>100% 5-year survival</li>
</ul>
</li>
</ul>
<h3 id="stage-i-ii-invasive-breast-cancer">Stage I - II - Invasive breast cancer</h3>
<ul>
<li>Investigations<ul>
<li>Not for PET/CT/Bone scan</li>
<li>Not for tumour markers (CA15-3, CA27-29)</li>
</ul>
</li>
<li>Therapeutic aim - curative</li>
<li>Management options: Surgical and adjuvant chemo/radiotherapy<ol>
<li>Surgery - primary<ol>
<li>Conservative approach - Wide excision and irradiation<ul>
<li>Indicated if &lt;= 5cm, no skin involvement and clear margins achieved</li>
</ul>
</li>
<li>Mastectomy +/- Neoadjuvant chemo/endocrine therapy<ul>
<li>if lumpectomy cannot be satisfactorily achieved OR</li>
<li>Inflammatory cancers OR</li>
<li>Skin involvement (e.g. Peau d'Orange) OR</li>
<li>BRCA1/2 mutations OR</li>
<li>Strong family history OR</li>
<li>if irradiation is contraindicated (needed for conservative approach)</li>
</ul>
</li>
</ol>
</li>
<li>Surgery - sentinel LN biopsy and axillary dissection<ul>
<li>If clinically positive lymph nodes → axillary dissection is RECOMMENDED</li>
<li>If sentinel lymph node cannot be identified → axillary dissection is RECOMMENDED</li>
<li>If sentinel lymph nodes identified AND<ul>
<li>&lt;= 2 involved → NO NEED for dissection</li>
<li>
<blockquote>
<p>=3 involved → axillary dissection is RECOMMENDED</p>
</blockquote>
</li>
</ul>
</li>
<li>Note see ../../..//IM/Oncology/Breast%20cancer.md../../..//IM/Oncology/Breast%20cancer.md<a href="#Axillary%20dissection%20complications">Axillary dissection complications</a></li>
</ul>
</li>
<li>Adjuvant Irradiation<ul>
<li>typically performed on whole breast</li>
<li>Recommended post-mastectomy if &gt;= 5cm, positive margins, skin involvement, inflammatory breast cancer, or &gt;=4 lymph nodes</li>
<li>reduces risk of local recurrence, metastases and improves overall survival</li>
<li><em>in a node negative setting, the addition of radiation to lumpectomy makes no difference on survival - just reduces risk of local recurrence</em></li>
</ul>
</li>
<li>Adjuvant hormonal therapy<ul>
<li>Indicated if &gt;= 70 years old, &lt;2cm, and no lymph node involvement</li>
<li>If ER positive - can accept just wide excision and antiestrogen therapy</li>
<li>can be used with whole breast irradiation<ul>
<li>reduces local recurrence</li>
<li>no effect on distant mets, breast cancer-specific survival or overall survival</li>
</ul>
</li>
<li>Adjuvant hormonal therapy for ER/PR positive<ul>
<li>Ovarian function suppression (OFS) if premenopauseal</li>
</ul>
</li>
<li>Adjuvant therapy for HER2 positivity</li>
</ul>
</li>
</ol>
</li>
</ul>
<h3 id="stage-iii-locally-invasive-nil-metastases">Stage III - Locally invasive, nil metastases</h3>
<ul>
<li>Investigations<ul>
<li>PET/Bone scan and whole body CT indicated (Staging)</li>
<li>Consider multigene assay (21 gene recurrence assay) to determine if adjuvant chemotherapy will be of benefit</li>
</ul>
</li>
<li>Therapeutic aim - potentially curable</li>
<li>Management options<ul>
<li>Neoadjuvant antiestrogen or chemotherapy</li>
<li>Surgery</li>
<li>Adjuvant radiotherapy</li>
</ul>
</li>
<li>Prognosis and followup<ul>
<li>Annual mammograms</li>
<li>Ongoing tamoxifen use - ensure yearly gynaecological exams, evaluate for abnormal bleeding<ul>
<li>avoid CTP2D6 inhibition (e.g. buproprion, fluoxetine)</li>
<li>review bone density every 2 years and consider antiresorptive therapy </li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 id="stage-iv-metastatic">Stage IV - Metastatic</h3>
<ul>
<li>Investigations<ul>
<li>Biopsy of the primary site</li>
<li>Biopsy of the upstaging secondary/metastatic site</li>
</ul>
</li>
<li>Therapeutic aim - symptom control and QoL</li>
<li>Management<ul>
<li>Hormonal therapy first line for ER +ve (unless there is a visceral crisis)<ul>
<li>AI +/-0 palbociclib for postmenopausal</li>
<li>tamoxifen + ovarian suppression for premenopausal</li>
</ul>
</li>
<li>aromatase inhibitor - anastrozole, letrozole, axemestane</li>
<li>fulvestrant - pure ER antagonist</li>
<li>targeted therapy<ul>
<li>palbociclib, ribociclib, abemaciclib - oral CDK 4/6 inhibitor  → increased progression free survival, but not oral survival (but could mean delaying starting chemo)</li>
<li>everolimus - oral mTOR inhibitor</li>
<li>immunotherapy - unclear how to maximise response</li>
</ul>
</li>
<li>chemotherapy has modest improvements in overall survival - main improvement is symptom control and palliation<ul>
<li>single agent chemo is less toxic than combined</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="_1"><img alt="" src="../../figures/Pasted%20image%2020231025120734.png" /></h2>
<h2 id="complications">Complications</h2>
<h3 id="axillary-dissection-complications">Axillary dissection complications</h3>
<ul>
<li>Complications include<ul>
<li>Lymphoedema</li>
<li>Sensory loss</li>
<li>Shoulder abduction defects</li>
</ul>
</li>
<li>only done when palpable lymph nodes at diagnosis</li>
</ul>
<hr />
<p>Evidence on breast cancer treatment
- tamoxifen, raloxifen, aromatase inhibitors - 40-60% reduction in breast cancer risk
    - only prevents ER+ breast cancer
    - no survival benefit seen - no benefit in primary prevention cohort
    - raloxifene and AIs only used after menopause
    - chemoprevention is not used due to absolute risk of breast cancer low</p>
<p><img alt="" src="../../figures/Pasted%20image%2020231025114943.png" /></p>
<hr />
<h2 id="bone-metastases">Bone metastases</h2>
<ul>
<li>70-75% of women with metastatic breast cancer will develop bone mets</li>
<li>complications<ul>
<li>pain</li>
<li>hypercalcaemia</li>
<li>pathological fractures</li>
<li>cord/nerve compressions</li>
</ul>
</li>
<li>routine bisphosphonates for bone mets have significantly improved QOL for metastatic patients</li>
</ul></div>
            </div>
        </div>

        <footer class="col-md-12">
            <hr>
                <p>Copyright &copy; 2021 Weber Liu</p>
            <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a>.</p>
        </footer>
        <script src="../../js/jquery-3.6.0.min.js"></script>
        <script src="../../js/bootstrap.min.js"></script>
        <script>
            var base_url = "../..",
                shortcuts = {"help": 191, "next": 78, "previous": 80, "search": 83};
        </script>
        <script src="../../js/base.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="../../search/main.js"></script>

        <div class="modal" id="mkdocs_search_modal" tabindex="-1" role="dialog" aria-labelledby="searchModalLabel" aria-hidden="true">
    <div class="modal-dialog modal-lg">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="searchModalLabel">Search</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
                <p>From here you can search these documents. Enter your search terms below.</p>
                <form>
                    <div class="form-group">
                        <input type="search" class="form-control" placeholder="Search..." id="mkdocs-search-query" title="Type search term here">
                    </div>
                </form>
                <div id="mkdocs-search-results" data-no-results-text="No results found"></div>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div><div class="modal" id="mkdocs_keyboard_modal" tabindex="-1" role="dialog" aria-labelledby="keyboardModalLabel" aria-hidden="true">
    <div class="modal-dialog">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="keyboardModalLabel">Keyboard Shortcuts</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
              <table class="table">
                <thead>
                  <tr>
                    <th style="width: 20%;">Keys</th>
                    <th>Action</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="help shortcut"><kbd>?</kbd></td>
                    <td>Open this help</td>
                  </tr>
                  <tr>
                    <td class="next shortcut"><kbd>n</kbd></td>
                    <td>Next page</td>
                  </tr>
                  <tr>
                    <td class="prev shortcut"><kbd>p</kbd></td>
                    <td>Previous page</td>
                  </tr>
                  <tr>
                    <td class="search shortcut"><kbd>s</kbd></td>
                    <td>Search</td>
                  </tr>
                </tbody>
              </table>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div>

    </body>
</html>
